Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?  

Ipi/nivo is much more toxic than single agent checkpoint inhibition with serious autoimmune-type side effects like "Triple M" Overlap Syndrome, myocarditis, pneumonitis, and hepatitis, and I would lean away from ipi/nivo for frail patients or older adults who are not robust. I think a careful geriat...

The increased toxicity of ipi/nivo compared to single-agent Nivolumab has to be taken into consideration when making treatment decisions for this population (especially when we do not yet have the final overall survival data). If I have a patient with underlying autoimmune concerns or who is older/m...